Evidence map›Paper›PMID 37545888›Full record

ArticleFrontiers in bioengineering and biotechnology2023

Impact of nanocarrier aggregation on EPR-mediated tumor targeting.

S P Surya Teja, N Damodharan, T Tamilanban, Vetriselvan Subramaniyan, V Chitra, Suresh V Chinni, Ling Shing Wong, Neeraj Kumar Fuloria, Mahendran Sekar, Shivkanya Fuloria and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

S P Surya TejaDepartment of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India.
N DamodharanDepartment of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India.
T TamilanbanDepartment of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India.
Vetriselvan SubramaniyanJeffrey Cheah School of Medicine and Health Sciences, Monash University, Bandar Sunway, Malaysia.
V ChitraDepartment of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India.
Suresh V ChinniDepartment of Biochemistry, Faculty of Medicine, Bioscience, and Nursing, MAHSA University, Jenjarom, Malaysia.
Ling Shing WongFaculty of Health and Life Sciences, INTI International University, Nilai, Malaysia.
Neeraj Kumar FuloriaFaculty of Pharmacy, AIMST University, Bedong, Malaysia.
Mahendran SekarSchool of Pharmacy, Monash University Malaysia, Subang Jaya, Selangor, Malaysia.
Shivkanya FuloriaFaculty of Pharmacy, AIMST University, Bedong, Malaysia.
Gobinath RamachawolranDepartment of Foundation, RCSI and UCD Malaysia Campus, Pinang, Malaysia.
Siddharthan SelvarajFaculty of Dentistry, AIMST University, Bedong, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the influence of excipients on retaining the particle size of methotrexate (MTX) loaded chitosan nanocarriers (CsNP) during lyophilization, which relates to the ability to enlarge the particle size and target specific areas. The nanocarriers were prepared using the ionic gelation technique with tripolyphosphate as a crosslinker. Three lyophilized formulations were used: nanosuspension without Lyoprotectant (NF), with mannitol (NFM), and with sucrose (NFS). The lyophilized powder intended for injection (PI) was examined to assess changes in particle size, product integrity, and comparative biodistribution studies to evaluate targeting ability. After lyophilization, NFS was excluded from

Indexed as

biodistributioncancer treatmentchitosanlyophilizationnanocompositetargeted tumor drug

Identifiers

PMID37545888
PMCPMC10402740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.